쓰리빌리언, 신생아 검사로 진단 확장…해외 비환자 매출 시험대

3billion's launch of 3B-Neo marks a strategic pivot from rare disease diagnosis to the high-growth genomic Newborn Screening (gNBS) market, significantly expanding its target demographic to non-symptomatic newborns. This move is crucial as it leverages the company's established global network to capture recurring revenue in the preventative healthcare sector, positioning genomic data as a standard for early-life health management.